title: Second-line age-adjusted International Prognostic Index in patients with advanced non-Hodgkin lymphoma after T-cell depleted allogeneic hematopoietic SCT.
abstract: T-cell depleted allogeneic hematopoietic SCT (TCD-HSCT) have shown durable disease-free survival with a low risk of GVHD in patients with AML. We investigated this approach in 61 patients with primary refractory or relapsed non-Hodgkin lymphoma (NHL), who underwent TCD-HSCT from January 1992 through September 2004. Patients received myeloablative cytoreduction consisting of hyperfractionated total body irradiation, followed by either thiotepa and cyclophosphamide (45 patients) or thiotepa and fludarabine (16 patients). We determined the second-line age-adjusted International Prognostic Index score (sAAIPI) before transplant transplant. Median follow-up of surviving patients is 6 years. The 10-year OS and EFS were 50% and 43%, respectively. The relapse rate at 10 years was 21% in patients with chemosensitive disease and 52% in those with resistant disease at time of HSCT. Nine of the 18 patients who relapsed entered a subsequent CR. OS (P=0.01) correlated with the sAAIPI. The incidence of grades II-IV acute GVHD was 18%. We conclude that allogeneic TCD-HSCT can induce high rates of OS and EFS in advanced NHL with a low incidence of GVHD. Furthermore, the sAAIPI can predict outcomes and may be used to select the most appropriate patients for this type of transplant.
authors.affiliation: Allogeneic Bone Marrow Transplantation Service, Memorial Sloan-Kettering Cancer Center, New York, NY 10065, USA. peralesm@mskcc.org
authors.forename: M-A
authors.initials: MA
authors.lastname: Perales
authors.forename: R
authors.initials: R
authors.lastname: Jenq
authors.forename: J D
authors.initials: JD
authors.lastname: Goldberg
authors.forename: A S
authors.initials: AS
authors.lastname: Wilton
authors.forename: S S E
authors.initials: SS
authors.lastname: Lee
authors.forename: H R
authors.initials: HR
authors.lastname: Castro-Malaspina
authors.forename: K
authors.initials: K
authors.lastname: Hsu
authors.forename: E B
authors.initials: EB
authors.lastname: Papadopoulos
authors.forename: M R M
authors.initials: MR
authors.lastname: van den Brink
authors.forename: F
authors.initials: F
authors.lastname: Boulad
authors.forename: N A
authors.initials: NA
authors.lastname: Kernan
authors.forename: T N
authors.initials: TN
authors.lastname: Small
authors.forename: S
authors.initials: S
authors.lastname: Wolden
authors.forename: N H
authors.initials: NH
authors.lastname: Collins
authors.forename: M
authors.initials: M
authors.lastname: Chiu
authors.forename: G
authors.initials: G
authors.lastname: Heller
authors.forename: R J
authors.initials: RJ
authors.lastname: O'Reilly
authors.forename: T
authors.initials: T
authors.lastname: Kewalramani
authors.forename: J W
authors.initials: JW
authors.lastname: Young
authors.forename: A A
authors.initials: AA
authors.lastname: Jakubowski
mesh_terms: D000293:Adolescent; D000328:Adult; D002648:Child; D002675:Child, Preschool; D018572:Disease-Free Survival; D005500:Follow-Up Studies; D006086:Graft vs Host Disease / Q000401:mortality; D018380:Hematopoietic Stem Cell Transplantation / Q000009:adverse effects / Q000401:mortality*; D006801:Humans; D015994:Incidence; D008212:Lymphocyte Depletion / Q000009:adverse effects / Q000401:mortality*; D008228:Lymphoma, Non-Hodgkin / Q000175:diagnosis / Q000401:mortality / Q000628:therapy; D008875:Middle Aged; D011237:Predictive Value of Tests; D011379:Prognosis; D012307:Risk Factors; D018183:Transplantation Chimera; D014184:Transplantation, Homologous; D055815:Young Adult